PIK3CA and breast carcinoma: The Society of Clinical Research on Oncology Medications of the China Anti‐Cancer Association, in collaboration with the Breast Cancer Expert Committee of the National Cancer Quality Control Center, the Society of Onco‐Pathology of the China Anti‐Cancer Association, and the Boao Cancer Innovation Institute, convened experts from relevant fields to develop the “Expert Consensus on the Clinical Application of PI3K/AKT/mTOR Inhibitors in the Treatment of Advanced Breast Cancer” in 2022 [19].